Superiority of escitalopram to paroxetine in the treatment of depression
Kasper, Siegfried, Baldwin, David S., Lönn, Sara Larsson and Boulenger, Jean-Philippe (2009) Superiority of escitalopram to paroxetine in the treatment of depression. European Neuropsychopharmacology, 19, (4), 229-237. (doi:10.1016/j.euroneuro.2008.12.003).
Full text not available from this repository.
Post-hoc pooled analysis of data from two 6-month randomised controlled trials in patients with major depressive disorder (MDD) revealed superior efficacy and tolerability of escitalopram when compared with paroxetine. Escitalopram (n = 394) produced a significantly (p < 0.01) greater mean treatment difference of 2.0 points in primary endpoints, judged using the Montgomery–Åsberg Depression Rating Scale (MADRS) total score, compared with paroxetine (n = 383). Significant differences were also observed in Clinical Global Impression (CGI) — severity (escitalopram, 2.1; paroxetine, 2.4; p < 0.01) and CGI — improvement (escitalopram, 1.8; paroxetine, 2.0: p < 0.01). In the sub-group of severely depressed patients (baseline MADRS ≥ 30), escitalopram showed further improved efficacy compared with paroxetine in all scores. This analysis supports previous observations of superior efficacy and tolerability of long-term escitalopram treatment (10 to 20 mg/day) compared with paroxetine (20 to 40 mg/day). Escitalopram is a good therapeutic option for the long-term treatment of MDD, particularly in severely depressed patients.
|Keywords:||escitalopram, major depressive disorder (MDD), selective serotonin reuptake inhibitors (SSRIs), severe depression, paroxetine|
|Subjects:||R Medicine > R Medicine (General)|
|Divisions:||University Structure - Pre August 2011 > School of Medicine > Clinical Neurosciences
University Structure - Pre August 2011 > School of Medicine
|Date Deposited:||27 Apr 2010 09:39|
|Last Modified:||06 Aug 2015 03:00|
|RDF:||RDF+N-Triples, RDF+N3, RDF+XML, Browse.|
Actions (login required)